Skip to main content

Table 5 Characteristics of patients with rheumatic diseases and pneumonia caused by K. pneumoniae with or without ESBL production

From: Klebsiella pneumoniae pneumonia in patients with rheumatic autoimmune diseases: clinical characteristics, antimicrobial resistance and factors associated with extended-spectrum β-lactamase production

Variables ESBL-positive (N = 23) ESBL-negative (N = 32) p value
Age (years) 48.0 ± 14.6 54.2 ± 18.0 0.096
Sex (female) 14 (60.9%) 17 (53.1%) 0.568
Duration of corticotherapy (months) 17.5 ± 37.0 29.3 ± 54.2 0.444
Dose of corticosteroids (mg) 72.3 ± 53.3 37.6 ± 28.4 0.015
Hospitalization within last 90 days 20 (87.0%) 23 (71.9%) 0.182
Previous antimicrobial therapy within 30 days 22 (95.7%) 25 (78.1%) 0.120
Diabetes mellitus 5 (21.7%) 9 (28.1%) 0.592
Fever 19 (82.6%) 23 (71.9%) 0.355
Cough/expectoration 18 (78.3%) 27 (84.4%) 0.726
Respiratory failure at admission 10 (43.5%) 14 (43.8%) 0.984
Blood leukocyte count (109/L)    0.035
 < 4 3 (13.0%) 4 (12.5%)  
 4–10 14 (60.9%) 9 (28.1%)  
 > 10 6 (26.1%) 19 (59.4%)  
Blood neutrophil count (109/L) 8.17 ± 5.99 9.13 ± 5.03 0.246
Blood lymphocyte count (/μL) 516 ± 291 1143 ± 1255 0.015
Albumin (g/L) 28.9 ± 4.8 30.2 ± 4.9 0.259
Urea (mmol/L) 9.71 ± 5.61 8.99 ± 7.37 0.187
C-reactive protein (mg/L) 66.0 ± 59.8 79.0 ± 69.7 0.703
PCT (ng/ml)    0.899
 < 0.5 15 (65.2%) 20 (62.5%)  
 0.5–2 3 (13.0%) 6 (18.8%)  
 2–10 4 (17.4%) 4 (12.5%)  
 > 10 1 (4.4%) 2 (6.2%)  
CMV viremia 12 (52.2%) 6 (18.8%) 0.009
  1. Data were presented as mean ± SD or numbers (%)